Completed NA INTERVENTIONAL 3-arm NCT00889434

Efficacy and Safety Study of EGCG/Tocotrienol in 18 Patients With Splicing-mutation-mediated Cystic Fibrosis (CF)

Single-site, Open-label, Dose-ranging, Efficacy, and Safety Study of EGCG/Tocotrienol in 18 Patients With Splicing-mutation-mediated CF

Sponsor: Hadassah Medical Organization

Conditions Cystic Fibrosis

Interventions ECGC EGCG + Tocotrienol Tocotrienol

Updated 6 times since 2017 Last updated: Nov 29, 2017 Started: Nov 1, 2011 Primary completion: Apr 16, 2015 Completion: Apr 16, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Cystic Fibrosis and is currently completed. Hadassah Medical Organization leads this study, which shows 6 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Mar 2017 — Jun 2018 [monthly]

Completed NA

Status: Unknown Status → Completed

▶ Show 1 earlier version

Jan 2017 — Mar 2017 [monthly]

Unknown Status NA

First recorded

Nov 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hadassah Medical Organization

Data source: Hadassah Medical Organization

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jerusalem, Israel